Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Director · 10% owner | July 28, 2022 | August 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date July 28, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,674,766 |
Reported balance
After 2022-07-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-07-28 · Grant · Acquired 3,253,796 · Balance 16,674,766 F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering at a price of $4.61 per share. F2: These shares are directly held by ElevateBio. David Hallal, Vikas Sinha, Morana Jovan-Embiricos and Ansbert Gadicke are directors of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. Such persons disclaim beneficial ownership of all shares held by ElevateBio except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering at a price of $4.61 per share.
F2: These shares are directly held by ElevateBio. David Hallal, Vikas Sinha, Morana Jovan-Embiricos and Ansbert Gadicke are directors of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. Such persons disclaim beneficial ownership of all shares held by ElevateBio except to the extent of their pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2022 Filed Aug 1, 2022 16:35 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 3,253,796 | $4.61 | $14,999,999.56 |
DisclosureSEC source: 0000899243-22-027169 · doc4.xml · nonDerivative · entry 1 ElevateBio, LLC · CIK 0001818060 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,674,766 F1 · kind: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering at a price of $4.61 per share. F2 · ownership.direct: These shares are directly held by ElevateBio. David Hallal, Vikas Sinha, Morana Jovan-Embiricos and Ansbert Gadicke are directors of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. Such persons disclaim beneficial ownership of all shares held by ElevateBio except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 20,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021579 · doc4.xml · derivative · entry 2 ElevateBio, LLC · CIK 0001818060 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,420,970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F2 · ownership.direct: Shares held by ElevateBio LLC ("ElevateBio"). David Hallal, Vikas Sinha, Morana Jovan-Embiricos and Ansbert Gadicke are directors of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. Such persons disclaim beneficial ownership of all shares held by ElevateBio except to the extent of their pecuniary interest therein, if any. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:44 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | ConversionCommon Stock | 13,420,970 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021579 · doc4.xml · nonDerivative · entry 1 ElevateBio, LLC · CIK 0001818060 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,420,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date. F2 · ownership.direct: Shares held by ElevateBio LLC ("ElevateBio"). David Hallal, Vikas Sinha, Morana Jovan-Embiricos and Ansbert Gadicke are directors of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. Such persons disclaim beneficial ownership of all shares held by ElevateBio except to the extent of their pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.